France-based microbome therapy developer Maat Pharma has raised €10m ($11m) in series A capital from investors including pharmaceutical company Biocodex.
CM-CIC Innovation led the funding, secured ‘within the context of Maat’s series A round’, with participation by venture capital firm Seventure Partners and French agricultural research institute Inra.
The capital will support the commencement of clinical studies for a drug candidate that will treat dysbiosis, a microbial imbalance which can follow the treatment of diseases like leukaemia, in summer this year.
Maat previously received €1m from Seventure Partners in late 2014 and another €1m from Seventure and Inra in July 2015.
Jean-Marie Lefèvre, chief executive of Biocodex, said: “Drawing on its expertise in the field of intestinal microbiota, Biocodex is delighted to support the development of Maat Pharma in its innovative and original project to correct dysbiosis.
This cooperation aims to provide new therapeutic solutions via the autologous transplantation of intestinal microbiota in the event of illnesses or treatments which have seriously altered it.”